HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells

Wolfgang Dichtl, Jozef Dulak, Matthias Frick, Hannes F. Alber, Severin P. Schwarzacher, Mikko P.S. Ares, Jan Nilsson, Otmar Pachinger, Franz Weidinger

Objective—Pleiotropic atheroprotective effects of HMG-CoA reductase inhibitors may be mediated on the level of vascular gene transcription. The aim of this study was to characterize the effects of statins on the activation of transcription factors known to regulate inflammation and cell proliferation/differentiation.

Methods and Results—Simvastatin, atorvastatin, and lovastatin (0.1 to 10 μmol/L) inhibited the binding of nuclear proteins to both the nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1) DNA consensus oligonucleotides in human endothelial and vascular smooth muscle cells as assessed by electrophoretic mobility shift assay (EMSA). The inhibitory effects of statins on NF-κB or AP-1–dependent transcriptional activity were examined by transient transfection studies. HMG-CoA reductase inhibitors upregulated IκB-α protein levels in endothelial cells and decreased c-Jun mRNA expression in smooth muscle cells as analyzed by Western and Northern blotting, respectively. Furthermore, statins inhibited DNA binding of hypoxia-inducible factor-1α. Downstream effects of statins included inhibition of plasminogen activator inhibitor-1 and vascular endothelial growth factor-A mRNA levels in endothelial cells.

Conclusions—HMG-CoA reductase inhibitors downregulate the activation of transcription factors NF-κB, AP-1, and hypoxia-inducible factor-1α. These findings support the concept that statins have antiinflammatory and antiproliferative effects that are relevant in the treatment of atherosclerotic diseases. (Arterioscler Thromb Vasc Biol. 2003;23:58-63.)

Key Words: statins ■ nuclear factor-κB ■ activator protein-1 ■ hypoxia-inducible factor-1α ■ vascular endothelial growth factor

Received May 19, 2002; revision accepted August 23, 2002.

From the Department of Internal Medicine (W.D., M.F., H.F.A., S.P.S., O.P., F.W.), Division of Cardiology, Leopold-Franzens-University Innsbruck, Austria; Wallenberg Laboratory (W.D., M.P.S.A., J.N.), Department of Medicine, Malmö University Hospital, Lund University, Sweden; and Department of Cell Biochemistry (J.D.), Institute of Molecular Biology and Biotechnology, Jagiellonian University, Krakow, Poland.

Correspondence to Wolfgang Dichtl, MD, PhD, Department of Internal Medicine, Division of Cardiology, Leopold-Franzens-Universität Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria. E-mail wolfgang.dichtl@uibk.ac.at

© 2003 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol. is available at http://www.atvbaha.org

DOI: 10.1161/01.ATV.0000043456.48735.20
Effects of Simvastatin, Atorvastatin, and Lovastatin on DNA Binding of Transcription Factor NF-κB, on NF-κB–Dependent Gene Expression in Human Endothelial and Vascular Smooth Muscle Cells, and on IκB-α Protein Levels in Human Endothelial Cells

As shown in Figure 1, simvastatin, atorvastatin, and lovastatin significantly inhibit basal NF-κB DNA binding activity (Ea.hy926 cells, lanes 1 through 6; human aortic endothelial cells, lanes 7 through 12; human aortic smooth muscle cells, lanes 13 through 17). As shown for simvastatin, this effect was already detected at doses of 0.1 μmol/L (lane 4). TNF-α–treated cells were used as a positive control (lanes 10 through 12), in which addition of antibodies directed against either p50 (lane 11) or p65 (lane 12) led to a marked supershift of the specific band (small arrow). Statins did not significantly affect nuclear protein binding to SP-1 consensus DNA sequences de-
Figure 1B shows SEAP activity in supernatants derived from Ea.hy926 cells 24 hours after incubation with 10 μmol/L simvastatin or 10ng/mL TNF-α, as follows: control 100% (n=4; SD±7.2); 10 μmol/L simvastatin 67% (n=4; SD±6.6; P=0.02); TNF-α 230.5% (n=4; SD±17.5); and TNF-α+10 μmol/L simvastatin 156.5% (n=4; SD±23.9; P=0.02). Simvastatin and atorvastatin but not lovastatin (at a concentration of 10 μmol/L) significantly decreased basal NF-κB activation also in human aortic smooth muscle cells, as shown in the left part of Figure 1B, as follows: control 100% (n=5; SD±13.4); 10 μmol/L simvastatin 69.6% (n=5; SD±12.9; P=0.008); 10 μmol/L atorvastatin 60.5% (n=5; SD±15.5; P=0.008); 10 μmol/L lovastatin 81.7% (n=5; SD±21.74; P=0.15).

Inhibition of NF-κB signaling by statins may be mediated by induction or stabilization of its cytosolic inhibitor IκB-α, because simvastatin, atorvastatin, and lovastatin increased IκB-α protein levels in Ea.hy926 cells within 2 hours of incubation (Figure 2B and data not shown).

**Effects of Simvastatin, Atorvastatin, and Lovastatin on DNA Binding of Transcription Factor AP-1, AP-1–Dependent Gene Expression, and c-Jun mRNA Expression in Human Endothelial and Vascular Smooth Muscle Cells**

The same nuclear extracts were additionally analyzed for binding to the AP-1 consensus sequence, as shown in Figure 3: atorvastatin, simvastatin, and lovastatin markedly decreased basal AP-1 DNA binding. This effect was dose-dependent and seen at concentrations >0.1 to 1 μmol/L, varying between different statins and cell types tested. In Ea.hy926 cells, atorvastatin profoundly diminished AP-1 activation at all doses tested (from 0.1 to 10 μmol/L; lanes 4, 5, 7, and 9), whereas lovastatin lead to such an inhibition at concentrations >1 μmol/L (lane 3). Simvastatin showed weaker potency to inhibit AP-1 activation (lane 12), and concentrations >1 μmol/L of simvastatin were needed to inhibit AP-1 activation in human aortic endothelial cells (HAECS) (lanes 14 through 16). Addition of antibodies either led to a supershift (anti-JunD, lane 21, small arrow) or decreased DNA-binding capacity (anti-c-Fos, anti-c-Jun, anti-JunB, lanes 18 through 20). Simvastatin clearly inhibited LPS-stimulated AP-1 activation at concentrations of and above 0.5 μmol/L (lanes 22 through 28). Similar effects were seen in smooth muscle cells, in which simvastatin decreased basal AP-1 DNA binding already at 0.1 μmol/L (lanes 29 through 35). Densitometric analysis of lanes 10 through 12 showed that 0.1 and 1 μmol/L simvastatin decreased AP-1 binding to consensus DNA sequences by 11.8% and 35.2%, respectively.

The effects of statins on AP-1–dependent gene activation in endothelial cells were studied by transient transfection with pAP-1-SEAP vectors. Figure 1A (available online at http://atvb.ahajournals.org) shows SEAP activity in supernatants derived from Ea.hy926 cells 24 hours after incubation with 10 μmol/L simvastatin, atorvastatin, and lovastatin, as follows: control 100% (n=4; SD±7.8); 10 μmol/L simvastatin 84.5% (n=5; SD±5.7; P=0.016); 10 μmol/L atorvastatin 72.4% (n=5; SD±8.1; P=0.009); and 10 μmol/L lovastatin 77.5% (n=5; SD±8.9; P=0.016).

C-Jun is a central component of most AP-1 complexes. As shown in Figure 1B, basal mRNA expression of the c-Jun gene (lanes 1 through 3) was decreased 10 hours after addition of either 10 μmol/L atorvastatin (lane 4), 10 μmol/L simvastatin (lane 5), or 10 μmol/L lovastatin (lane 6) in aortic smooth muscle cells. The corresponding blotting filter stained with methylene blue showing the 28S and 18S ribosomal RNAs demonstrates that approximately equal amounts of RNA were loaded.

**Effects of Simvastatin, Atorvastatin, and Lovastatin on DNA Binding of Transcription Factor HIF-1α in Human Endothelial and Vascular Smooth Muscle Cells and Effects of Atorvastatin and Lovastatin on VEGF-A/PAI-1 mRNA Expression in Human Endothelial Cells**

As shown in Figure 4, atorvastatin, simvastatin, and, to a lesser extent, lovastatin decreased DNA binding to the hypoxia-responsive element (HRE) in endothelial cells (lanes 1 through 12 and data not shown). TNF-α diminished HIF-1α activation in endothelial cells as well (lanes 5 and 9), an effect additionally enhanced on addition of statins (lanes 6 and 10). Statins also decreased HIF-1α DNA binding in smooth muscle cells (lanes 13 through 19), but this inhibition was.
weaker compared with endothelial cells. Addition of a supershift antibody directed against HIF-1α led to the complete disappearance of the specific band (lanes 11 and 12). Addition of 50-times excess of unlabeled HRE oligonucleotides but not of mutant unlabeled HRE oligonucleotides led to a decrease of the specific band (lanes 21 and 22).

Simvastatin has recently been shown to decrease basal and stimulated PAI-1 mRNA and protein expression in human endothelial cells.10 As assessed by Northern blotting, atorvastatin and lovastatin at concentrations of 1, 5, and 10 µmol/L decreased basal mRNA levels of PAI-1 as well (Figure II, available online at http://atvb.ahajournals.org). The same membranes was additionally hybridized for VEGF-A, showing that both statins also inhibited VEGF-A mRNA levels. The corresponding blotting filters stained with methylene blue showing the 28S and 18S ribosomal RNAs demonstrated that approximately equal amounts of RNA were loaded.

**Effects of Statins at Different Concentrations on Cell Viability**

A cytotoxicity assay based on LDH release was performed using the Promega CytoTox 96 assay. After 24 hours of incubation, there was no significant increase in LDH release, even when cells had been exposed to 10 µmol/L of statin treatment, as shown in Ea.hy926 cells as follows: control 100% (n=6); simvastatin 10 µmol/L 109.9% (n=6; SD±13.2); atorvastatin 10 µmol/L 110.3% (n=6; SD±7.3); and lovastatin 10 µmol/L 94% (n=6; SD±9.6). Similar results were obtained in HAECs and smooth muscle cells (data not shown). There was no sign of cytotoxicity after 24 hours of incubation of these experimental compounds (up to 10 µmol/L) as assessed by MTT assay, as shown in Ea.hy926 cells (data not shown). In contrast, statins even at the lowest doses tested significantly decreased WST reduction, as shown in Ea.hy926 cells as follows: control 100% (n=6), simvastatin 0.1 µmol/L 74.84% (n=6; SD±5.43); simvastatin 1 µmol/L 64.83% (n=6; SD±5.16); simvastatin 5 µmol/L 70.47% (n=6; SD±7.71); simvastatin 10 µmol/L 70.84% (n=6; SD±4.7); atorvastatin 0.1 µmol/L 93.61% (n=6; SD±11.35); atorvastatin 1 µmol/L 81.47% (n=6; SD±8.58); atorvastatin 5 µmol/L 74.26% (n=6; SD±9.96); atorvastatin 10 µmol/L 74.27% (n=6; SD±10.1); lovastatin 0.1 µmol/L 89.89% (n=6; SD±13.99); lovastatin 1 µmol/L 82.83% (n=6; SD±9.25); lovastatin 5 µmol/L 92.72% (n=6; SD±13.51); and lovastatin 10 µmol/L 87.9% (n=6; SD±9.54). Decreased availability of superoxide anion whose formation is inhibited by statins may explain these findings.14 Reduction of WST but not of MTT by NADH is strongly inhibited by superoxide dismutase, indicating involvement of superoxide in the reductive mechanism.15 Trypan blue exclusion assays were performed at conclusion of most of the experiments and demonstrated >95% viability with no differences between control and statin-treated groups (data not shown).

**Discussion**

In this study, we show that statins inhibit the activation of transcription factors NF-κB, AP-1, and HIF-1α in cultured human endothelial and vascular smooth muscle cells. NF-κB has been recognized as one of the major transcription factors influencing key steps in the development of atherosclerotic lesions. NF-κB profoundly regulates the expression of a variety of genes entangled in vascular diseases, which mediate cell migration, promote inflammation, and control the balance between cell proliferation and apoptosis.16 The activation of NF-κB is involved in endothelial dysfunction and seems to be linked to its redox sensitivity.17 The latter phenomenon could explain the inhibitory effects of statins on NF-κB activation, because statins are able to scavenge oxygen-free radicals18 in addition to the stimulated endothelial nitric oxide production that inhibits NF-κB via the induction and stabilization of IκB-α.19 Activated NF-κB is present in human atherosclerotic plaque, whereas little activated NF-κB can be detected in vessels free of atherosclerosis.20 Patients with unstable but not with stable angina pectoris have high levels of activated NF-κB in buffy coat-derived cells,21 and data suggest that blockade of NF-κB in vivo prevents myocardial infarction.22 Previous studies showed conflicting results regarding the interaction of statins and NF-κB signaling. Atorvastatin reduces activation of transcription factor NF-κB in cultured vascular smooth muscle and mononuclear cells23 as well as in atherosclerotic
lesions in the rabbit. Decreased NF-κB activity in mesangial cells has been detected on treatment with lovastatin, whereas simvastatin has been found to increase NF-κB activation in endothelial cells. Our investigations, being the first to use transient transfection techniques and to compare different statins at various concentrations, clearly support the notion that HMG-CoA reductase inhibitors curtail NF-κB signaling. In view of the role of NF-κB on inflammation and cell survival, the inhibition of basal as well as stimulated NF-κB activation may contribute to the antiinflammatory, antiproliferative, and proapoptotic effects of statins.

Another transcription factor involved in the progression of atherosclerosis is AP-1, a collective term referring to dimeric proteins composed of Jun, Fos, or ATF (activating transcription factor) subunits. AP-1–regulated genes include matrix metalloproteinases, cytokines, chemokines, adhesion molecules, inducible nitric oxide synthase, cell cycle proteins, and Fas ligand. Our investigations show that statins markedly decrease basal vascular AP-1 activation. Furthermore, statins inhibited basal mRNA expression of c-Jun, which is a central component of all AP-1 complexes and whose expression is regulated by positive feedback mechanisms via AP-1 binding to the TPA responsive element within its promoter. Effects of statins on AP-1 DNA binding may be mediated at the level of small GTP proteins by inhibited farnesylation of Ras or geranylgeranylation of Rho. Ras leads to the activation of Raf, an initial kinase of the mitogen-activated protein kinase cascade, which results in AP-1 activation via phosphorylation of extracellular signal–regulated kinases. The observed inhibition of AP-1 signaling could explain some of the plaque-stabilizing effects of HMG-CoA reductase inhibitors, eg, decreased expression of metalloproteinases (MMPs) or PAI-1. Our findings are supported by previous studies showing that lovastatin inhibits platelet-derived growth factor–mediated and angiotensin II–mediated c-Jun and c-Fos expression in human smooth muscle cells and the proliferation of renal epithelial tubular cells through a p21WAF1-activated, AP-1–dependent pathway. Decreasing effects of statins on AP-1 signaling detected in transfection experiments were weaker compared with the EMSA findings. This might be explained by the fact that transcriptional cofactors may compensate some of the inhibition of AP-1 binding proteins as well as that additional signaling pathways contribute to transcriptional activation, which are not affected by statins.

Hypoxia-inducible transcription factors (HIF-1α, HIF-1β, and HIF-2α) are now recognized as strongly influencing vascular gene transcription. The expression and activity of the HIF-1α subunit, which forms heterodimers with HIF-1β, are tightly regulated by cellular O2 concentrations. Under hypoxic conditions, HIF-1α activates the transcription of genes encoding erythropoietin, glucose transporters, glycolytic enzymes, VEGF and its receptors (VEGFR1, VEGFR2), and other genes whose protein products increase O2 delivery or facilitate metabolic adaption to hypoxia. HIFs also induce the expression of genes involved in vascular tone, cell growth, and inflammation. However, the role of transcription factor HIF-1α in the pathogenesis of atherosclerosis is less well established. Therefore, the pathogenic implications of the inhibitory effect of statins on HIF-1α binding to the HRE must remain speculative. Acute hypoxia causes pulmonary vasoconstriction, and chronic hypoxia causes smooth muscle replication and extracellular matrix accumulation, resulting in vessel wall remodeling. Hypoxia suppresses both the transcriptional rate of the endothelial nitric oxide synthase gene and decreases the stability of its mRNA, effects that were blocked by statins. Many genes, such as PAI-1, endothelin-1, and platelet-derived growth factor-B, whose expression are downregulated on statin treatment, contain HRE elements in their promoter regions.

Effects of statins on signaling cascades may also be influenced by their profound effects on membrane fatty acid composition, eg, by a stimulated desaturation of linoleic acid (LA, 18:2 n-6) yielding increased arachidonic acid levels. Linoleic acid stimulates both NF-κB and AP-1 activation in vascular cells, whereas arachidonic acid decreases NF-κB signaling.

Our findings that statins inhibit HIF-1α signaling and decrease VEGF expression in vascular cells are supported by several recently published studies. Simvastatin attenuates hypoxia-mediated effects in coronary artery walls of pigs in experimental hypercholesterolemia, such as upregulation of HIF-1α, VEGF, MMP-2, and MMP-9 immunoreactivity. Cerivastatin inhibits endothelial cell migration, and plasma levels of VEGF in patients with hypercholesterolemia are decreased on treatment with fluvastatin as well as with atorvastatin. Such previously suggested antiangiogenic effects of statins should be considered for delaying atherosclerotic plaque growth but might also inhibit tumor progression. This has been supported by clinical studies that have demonstrated that statin treatment reduced the incidence of cancers. Whether statins decrease VEGF mRNA expression under normoxic conditions attributable to decreased binding of NF-κB, AP-1, or HIF-1α to the promoter remains to be investigated.

In conclusion, this study shows that statins profoundly influence the expression and activation of transcription factors. Such interactions may affect local gene transcription in atherosclerotic vessels and thereby inhibit inflammation, thrombosis, and cell proliferation. Additional studies are required to test whether statin treatment in CAD patients regulates gene transcription in a comparable manner in vivo.

Dr Dukas is supported by a fellowship from the Austrian Society of Cardiology. The authors appreciate the technical help of Eva-Maria Mair.

References


HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells
Wolfgang Dichtl, Jozef Dulak, Matthias Frick, Hannes F. Alber, Severin P. Schwarzacher, Mikko P.S. Ares, Jan Nilsson, Otmar Pachinger and Franz Weidinger

Arterioscler Thromb Vasc Biol. 2003;23:58-63; originally published online October 24, 2002; doi: 10.1161/01.ATV.0000043456.48735.20
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/23/1/58

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/